<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="134617">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02070679</url>
  </required_header>
  <id_info>
    <org_study_id>UMSU-Cardiology-1</org_study_id>
    <nct_id>NCT02070679</nct_id>
  </id_info>
  <brief_title>Efficacy of Vitamin E in Preventing Contrast-Induced Acute Kidney Injury Following Coronary Angiography</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Urmia University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Urmia University of Medical Sciences</source>
  <oversight_info>
    <authority>Iran: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of vitamin E on preventing from
      incidence of contrast induced acute kidney injury  (CI-AKI) in the patients who undergone
      coronary angiography.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>The development of CI-AKI in group receiving vitamin E compared with placebo</measure>
    <time_frame>Within 72 hours after coronary angiography</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the serum level of Cr and the amount of eGFR</measure>
    <time_frame>Within 72 hours</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">290</enrollment>
  <condition>Stable Angina</condition>
  <condition>Unstable Angina</condition>
  <condition>Non ST Segment Elevation Myocardial Infarction</condition>
  <condition>Post MI</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vit-E</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>600 IU on 12 hours before angiography and 400 IU on 2 hours before angiography</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin E</intervention_name>
    <arm_group_label>Vit-E</arm_group_label>
    <other_name>Alpha-tocopherol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. All patients whon have either stable coronary artery disease (CAD) or recent acute
             coronary disease (ACS) and are scheduled for coronary angiography.

          2. Patients who have eGFR ≤60 ml/min/1.73 m2

        Exclusion Criteria:

          1. Allergy to contrast media

          2. Cardiogenic shock

          3. Pulmonary edema

          4. Overt cardiac failure or left ventricular ejection fraction ≤ 30%

          5. Acute kidney injury

          6. The history of receiving contrast media for any medical diagnostic or therapeutic
             procedures during previous 5 days

          7. The history of dialysis

          8. Being pregnant

          9. Having recent acute myocardial infarction

         10. Taking antioxidants and nephrotoxic drugs including NSAID and ACE-I on previous 2
             days
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Mir Hossein Seyyed-Mohammadzad, Interventionist</last_name>
    <phone>+989143458377</phone>
    <email>mmohammadzad@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yousef Rezaei</last_name>
    <phone>+989126231864</phone>
    <email>yousefrezaei1986@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seyyed-al-Shohada Heart Center, UMSU</name>
      <address>
        <city>Urmia</city>
        <state>West-Azerbaijan</state>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mir Hossein Seyyed-Mohammadzad</last_name>
      <phone>+989143458377</phone>
      <email>mmohammadzad@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Yousef Rezaei, GP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taleghani Hospital, UMSU</name>
      <address>
        <city>Urmia</city>
        <state>West-Azerbaijan</state>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 21, 2014</lastchanged_date>
  <firstreceived_date>February 21, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Urmia University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Chancellor of research</investigator_full_name>
    <investigator_title>Mir Hossein Seyyed-Mohammadzad</investigator_title>
  </responsible_party>
  <keyword>Alpha-tocopherol</keyword>
  <keyword>Vitamin E</keyword>
  <keyword>Contrast-Induced Acute Kidney Injury</keyword>
  <keyword>Coronary angiography</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Angina, Unstable</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Alpha-Tocopherol</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
